Immune mechanisms and novel pharmacological therapies of acute kidney injury

Current Drug Targets

Volumn 10, Issue 12, 2009, Pages 1196-1204

  Bajwa, Amandeep ^a   Kinsey, Gilbert R ^a   Okusa, Mark D ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Acute renal failure; Cisplatin; Inflammation; Ischemia reperfusion injury

Indexed keywords

4 [3 [6 AMINO 9 (5 ETHYLCARBAMOYL 3,4 DIHYDROXYTETRAHYDRO 2 FURYL) 9H PURIN 2 YL] 2 PROPYNYL]CYCLOHEXANECARBOXYLIC ACID METHYL ESTER; 5 (4 PHENYL 5 TRIFLUOROMETHYL 2 THIENYL) 3 (3 TRIFLUOROMETHYLPHENYL) 1,2,4 OXADIAZOLE; ACTIVATED PROTEIN C; ADENOSINE A1 RECEPTOR ANTAGONIST; ADENOSINE DERIVATIVE; CD11B ANTIGEN; CD69 ANTIGEN; ERYTHROPOIETIN; FINGOLIMOD; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 23; INTERLEUKIN 4; NORPHENAZONE; PHOSPHODIESTERASE INHIBITOR; PIRINIXIC ACID; PLACEBO; PRAVASTATIN; SIMVASTATIN; SPHINGOSINE 1 PHOSPHATE RECEPTOR; STOBADINE; THROMBOMODULIN; TOLL LIKE RECEPTOR; TOLL LIKE RECEPTOR 2; TUMOR NECROSIS FACTOR ALPHA;

ACUTE KIDNEY FAILURE; ADAPTIVE IMMUNITY; ANTIGEN PRESENTING CELL; B LYMPHOCYTE; BLOOD VESSEL PERMEABILITY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DENDRITIC CELL; ENDOTHELIUM CELL; EPITHELIUM CELL; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; KIDNEY EPITHELIUM; KIDNEY ISCHEMIA; MACROPHAGE; NATURAL KILLER CELL; NEUTROPHIL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; REPERFUSION INJURY; REVIEW; STEM CELL; T LYMPHOCYTE;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELL SURVIVAL; DISEASE MODELS, ANIMAL; HUMANS; INFLAMMATION; KIDNEY FAILURE, ACUTE; REPERFUSION INJURY;

EID: 72849107259     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789753174     Document Type: Review

References (126)

1. Xue JL, Daniels F, Star RA, Kimmel PL, Eggers PW, Molitoris BA, et al. Incidence and mortality of acute renal failure in Medicare beneficiaries, 1992 to 2001. J Am Soc Nephrol 2006; 17:1135-1142
2. Waikar SS, Curhan GC, Wald R, McCarthy EP, Chertow GM. Declining mortality in patients with acute renal failure, 1988 to 2002. J Am Soc Nephrol 2006; 17: 1143-1150
3. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, et al. Acute renal failure in critically ill patients: a multinational, multicenter study. JAMA 2005; 294: 813-818 (Pubitemid 41175724)
4. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004; 8: R204-12.
5. Liano F, Pascual J. Outcomes in acute renal failure. Semin Nephrol 1998; 18: 541-550
6. Hoste EA, Schurgers M. Epidemiology of acute kidney injury: how big is the problem? Crit Care Med 2008; 36: S146-51.
7. Chertow GM, Levy EM, Hammermeister KE, Grover F, Daley J. Independent association between acute renal failure and mortality following cardiac surgery. Am J Med 1998; 104: 343-348 (Pubitemid 28211024)
8. Levy EM, Viscoli CM, Horwitz RI. The effect of acute renal failure on mortality. A cohort analysis. JAMA 1996; 275: 1489-1494
9. Schrier RW, Wang W, Poole B, Mitra A. Acute renal failure: definitions, diagnosis, pathogenesis, and therapy. J Clin Invest 2004; 114: 5-14. (Pubitemid 39071636)
10. Thadhani R, Pascual M, Bonventre JV. Acute renal failure. N Engl J Med 1996; 334: 1448-1460
11. Bonventre JV, Weinberg JM. Recent advances in the pathophysiology of ischemic acute renal failure. J Am Soc Nephrol 2003; 14: 2199-2210 (Pubitemid 36909930)
12. Rabb H. The T cell as a bridge between innate and adaptive immune systems: implications for the kidney. Kidney Int 2002; 61:1935-1946 (Pubitemid 34539311)
13. Li L, Okusa MD. Blocking the Immune respone in ischemic acute kidney injury: the role of adenosine 2A agonists. Nat Clin Pract Nephrol 2006; 2: 432-444 (Pubitemid 44174535)
14. Friedewald JJ, Rabb H. Inflammatory cells in ischemic acute renal failure. Kidney Int 2004; 66: 486-491 (Pubitemid 38981983)
15. Devarajan P. Update on mechanisms of ischemic acute kidney injury. J Am Soc Nephrol 2006; 17: 1503-1520 (Pubitemid 43841396)
16. Sutton TA, Mang HE, Campos SB, Sandoval RM, Yoder MC, Molitoris BA. Injury of the renal microvascular endothelium alters barrier function after ischemia. Am J Physiol Renal Physiol 2003;285: F191-8.
17. Brodsky SV, Yamamoto T, Tada T, Kim B, Chen J, Kajiya F, et al. Endothelial dysfunction in ischemic acute renal failure: rescue by transplanted endothelial cells. Am J Physiol Renal Physiol 2002 Jun; 282: F1140-9.
18. Kelly KJ, Williams WW, Colvin RB, Meehan SM, Springer TA, Gutierrez-Ramos J, et al. Intercellular adhesion molecule-1- deficient mice are protected against ischemic renal injury. J Clin Invest 1996; 97: 1056-1063 (Pubitemid 26070586)
19. Singbartl K, Green SA, Ley K. Blocking P-selectin protects from ischemia/reperfusion-induced acute renal failure. FASEB J 2000;14: 48-54. (Pubitemid 30051522)
20. Okusa MD, Linden J, Huang L, Rieger JM, Macdonald TL, Huynh LP A2a-Adenosine receptor mediated inhibition of renal injury and neutrophil adhesion. Am J Physiol 2000; 279: F809-18.
21. Oh DJ, Dursun B, He Z, Lu L, Hoke TS, Ljubanovic D, et al. Fractalkine receptor (CX3CR1) inhibition is protective against ischemic acute renal failure in mice. Am J Physiol Renal Physiol 2008; 294: F264-71.
22. Li L, Huang L, Sung SS, Vergis AL, Rosin DL, Rose CE Jr, et al The chemokine receptors CCR2 and CX3CR1 mediate monocyte/macrophage trafficking in kidney ischemia-reperfusion injury. Kidney Int 2008; 74: 1526-1537
23. Thurman JM, Ljubanovic D, Royer PA, Kraus DM, Molina H, Barry NP, et al. Altered renal tubular expression of the complement inhibitor Crry permits complement activation after ischemia/reperfusion. J Clin Invest 2006; 116: 357-368 (Pubitemid 43228352)
24. Thurman JM, Lenderink AM, Royer PA, Coleman KE, Zhou J, Lambris JD, et al. C3a is required for the production of CXC chemokines by tubular epithelial cells after renal ishemia/ reperfusion. J Immunol 2007; 178: 1819-1828 (Pubitemid 46154654)
25. Leemans JC, Stokman G, Claessen N, Rouschop KM, Teske GJ, Kirschning CJ, et al. Renal-associated TLR2 mediates ischemia/reperfusion injury in the kidney. J Clin Invest 2005; 115: 2894-2903 (Pubitemid 41434417)
26. Wu H, Chen G, Wyburn KR, Yin J, Bertolino P, Eris JM, et al. TLR4 activation mediates kidney ischemia/reperfusion injury. J Clin Invest 2007; 117: 2847-2859 (Pubitemid 47529615)
27. Soos TJ, Sims TN, Barisoni L, Lin K, Littman DR, Dustin ML, et al. CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. Kidney Int 2006; 70: 591-596 (Pubitemid 44141588)
28. Li L, Huang L, Sung SJ, Lobo PI, Brown MG, Gregg RK, et al. NKT cell activation mediates neutrophil IFN-gamma production and renal ischemia-reperfusion injury. J Immunol 2007; 178: 5899-5911 (Pubitemid 46674387)
29. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD Resident dendritic cells are the predominant TNF-secreting cell in early renal ischemia-reperfusion injury. Kidney Int 2007; 71: 619-628 (Pubitemid 46494569)
30. Okusa MD. The inflammatory cascade in acute ischemic renal failure. Nephron 2002; 90: 133-138 (Pubitemid 34701986)
31. Koo DD, Welsh KI, Roake JA, Morris PJ, Fuggle SV. Ischemia/reperfusion injury in human kidney transplantation: an immunohistochemical analysis of changes after reperfusion. Am J Pathol 1998; 153: 557-566
32. Day YJ, Huang L, Ye H, Linden J, Okusa MD. Renal ischemiareperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages. Am J Physiol Renal Physiol 2005;288: F722-31.
33. Jo SK, Sung SA, Cho WY, Go KJ, Kim HK. Macrophages contribute to the initiation of ischaemic acute renal failure in rats. Nephrol Dial Transplant 2006; 21: 1231-1239
34. Zhang ZX, Wang S, Huang X, Min WP, Sun H, Liu W, et al. NK cells induce apoptosis in tubular epithelial cells and contribute to renal ischemia-reperfusion injury. J Immunol 2008; 181: 7489-7498
35. Day Y-J, Huang L, Ye H, Li L, Linden J, Okusa MD. Renal ischemia-reperfusion and adenosine 2A receptor-mediated tissue protection: The role of CD4+ T cells and inteferon gamma J. Immunol 2006; 176: 3108-3114 (Pubitemid 43306973)
36. Burne MJ, Daniels F, El Ghandour A, Mauiyyedi S, Colvin RB, O'Donnell MP, et al. Identification of the CD4+ T cell as a major pathogenic factor in ischemic acute renal failure. J Clin Invest 2001; 108: 1283-1290 (Pubitemid 33107755)
37. Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA. Alpha-melanocyte-stimulating hormone protects against renal injury after Ischemia in mice and rats. J Clin Invest 1997; 99:1165-1172 (Pubitemid 27142751)
38. Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol 2005; 5: 953-964
39. Anderson CF, Mosser DM. A novel phenotype for an activated macrophage: the type 2 activated macrophage. J Leukoc Biol 2002;72: 101-106
40. Geissmann F, Jung S, Littman DR. Blood monocytes consist of two principal subsets with distinct migratory properties. Immunity 2003; 19: 71-82. (Pubitemid 36859902)
41. Ricardo SD, van Goor H, Eddy AA. Macrophage diversity in renal injury and repair. J Clin Invest 2008; 118: 3522-3530
42. Ferenbach D, Hughes J. Macrophages and dendritic cells: what is the difference? Kidney Int 2008; 74: 5-7.
43. Satpute SR, Park JM, Jang HR, Agreda P, Liu M, Gandolfo MT, et al. The role for T cell repertoire/antigen-specific interactions in experimental kidney ischemia reperfusion injury. J Immunol 2009;183: 984-992
44. Dong X, Swaminathan S, Bachman LA, Croatt AJ, Nath KA, Griffin MD Antigen presentation by dendritic cells in renal lymph nodes is linked to systemic and local injury to the kidney. Kidney Int 2005; 68: 1096-1108 (Pubitemid 43246426)
45. Jang MH, Sougawa N, Tanaka T, Hirata T, Hiroi T, Tohya K, et al. CCR7 is critically important for migration of dendritic cells in intestinal lamina propria to mesenteric lymph nodes. J Immunol 2006; 176: 803-810 (Pubitemid 43099676)
46. Savransky V, Molls RR, Burne-Taney MJ, Chien C-C, Racusen L, Rabb H. Role of T cell receptor in kidney ischemia reperfusion injury. Kidney Int 2006. 69, 233-238 (Pubitemid 43323072)
47. Faubel S, Ljubanovic D, Poole B, Dursun B, He Z, Cushing S, et al. Peripheral CD4 T-cell depletion is not sufficient to prevent ischemic acute renal failure. Transplantation 2005; 80: 643-649 (Pubitemid 41377752)
48. Ascon M, Ascon DB, Liu M, Cheadle C, Sarkar C, Racusen L, et al. Renal ischemia-reperfusion leads to long term infiltration of activated and effector-memory T lymphocytes. Kidney Int 2009;75: 526-535
49. Krause D, Cantley LG. Bone marrow plasticity revisited: protection or differentiation in the kidney tubule? J Clin Invest 2005; 115: 1705-1708
50. Gupta S, Verfaillie C, Chmielewski D, Kren S, Eidman K, Connaire J, et al. Isolation and characterization of kidney-derived stem cells. J Am Soc Nephrol 2006; 17: 3028-3040 (Pubitemid 44707763)
51. Chen J, Park HC, Addabbo F, Ni J, Pelger E, Li H, et al. Kidneyderived mesenchymal stem cells contribute to vasculogenesis, angiogenesis and endothelial repair. Kidney Int 2008; 74: 879-889
52. Lin F. Stem cells in kidney regeneration following acute renal injury. Pediatr Res 2006; 59: 74R-8R.
53. Togel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31-42.
54. Sotiropoulou PA, Perez SA, Gritzapis AD, Baxevanis CN, Papamichail M. Interactions between human mesenchymal stem cells and natural killer cells. Stem Cells 2006; 24(1): 74-85.
55. Jiang XX, Zhang Y, Liu B, Zhang SX, Wu Y, Yu XD, et al. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 2005; 105: 4120-4126 (Pubitemid 40656164)
56. Humphreys BD, Valerius MT, Kobayashi A, Mugford JW, Soeung S, Duffield JS, et al. Intrinsic epithelial cells repair the kidney after injury. Cell Stem Cell 2008; 2: 284-291 (Pubitemid 351298594)
57. Gordon S. Alternative activation of macrophages. Nat Rev Immunol 2003; 3: 23-35.
58. Kerjaschki D. The crucial role of macrophages in lymphangiogenesis. J Clin Invest 2005; 115: 2316-2319
59. Duffield JS, Forbes SJ, Constandinou CM, Clay S, Partolina M, Vuthoori S, et al. Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest 2005; 115: 56-65. (Pubitemid 40385505)
60. Jang HS, Kim J, Park YK, Park KM. Infiltrated macrophages contribute to recovery after ischemic injury but not to ischemic preconditioning in kidneys. Transplantation 2008; 85: 447-455 (Pubitemid 351322770)
61. Fontenot JD, Gavin MA, Rudensky AY. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003; 4: 330-336
62. Shevach EM. Mechanisms of foxp3+ T regulatory cell-mediated suppression. Immunity 2009; 30: 636-645
63. Ascon DB, Ascon M, Satpute S, Lopez-Briones S, Racusen L, Colvin RB, et al. Normal mouse kidneys contain activated and CD3+CD4- CD8- double-negative T lymphocytes with a distinct TCR repertoire. J Leukoc Biol 2008; 84: 1400-1409
64. Kinsey GR, Sharma R, Huang L, Li L, Vergis AL, Ye H, et al. Regulatory T Cells Suppress Innate Immunity in Kidney Ischemia-Reperfusion Injury. J Am Soc Nephrol 2009; 20: 1744-1753
65. Monteiro RM, Camara NO, Rodrigues MM, Tzelepis F, Damiao MJ, Cenedeze MA, et al. A role for regulatory T cells in renal acute kidney injury. Transpl Immunol 2009; 21: 50-55
66. Jo SK, Rosner MH, Okusa MD. Pharmacologic treatment of acute kidney injury. why drugs haven't: why drugs haven't worked and what is on the horizon. Clin J Am Soc Nephrol 2007; 2: 256-365.
67. Spiegel S, Milstien S. Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 2003; 4: 397-407.
68. Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem 2002 14; 277: 21453-21457 (Pubitemid 34952287)
69. Awad AS, Ye H, Huang L, Li L, Foss Jr FW, Macdonald TL, et al. Selective Sphingosine 1-Phosphate 1 (S1P1) Receptor Activation Reduces Ischemia-Reperfusion Injury in Mouse Kidney. Am J Physiol Renal Physiol 2006; 290: F1516-24.
70. Lien YH, Yong KC, Cho C, Igarashi S, Lai LW. S1P(1)-selective agonist, SEW2871, ameliorates ischemic acute renal failure. Kidney Int 2006; 69: 1601-1608
71. Foss FW Jr, Clemens JJ, Davis MD, Snyder AH, Zigler MA, Lynch KR, et al. Synthesis, stability, and implications of phosphothioate agonists of sphingosine-1-phosphate receptors. Bioorg Med Chem Lett 2005; 15: 4470-4474
72. Jo SK, Bajwa A, Awad AS, Lynch KR, Okusa MD. Sphingosine-1-phosphate receptors: biology and therapeutic potential in kidney disease. Kidney Int 2008; 73: 1220-1230 (Pubitemid 351693151)
73. Kappos L, Antel J, Comi G, Montalban X, O'Connor P, Polman CH, et al. Radue EW Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006; 355: 1124-1140
74. Vallon V, Muhlbauer B, Osswald H. Adenosine and kidney function. Physiol Rev 2006; 86: 901-940
75. Linden J. Molecular approach to adenosine receptors: receptor mediated mechanisms of tissue protection. Annu Rev Pharmacol Toxicol 2001; 41: 775-787 (Pubitemid 32385906)
76. Bagshaw SM, Ghali WA. Theophylline for prevention of contrastinduced nephropathy: a systematic review and meta-analysis. Arch Intern Med 2005; 165: 1087-1093 (Pubitemid 40720732)
77. Kapoor A, Kumar S, Gulati S, Gambhir S, Sethi RS, Sinha N. The role of theophylline in contrast-induced nephropathy: a casecontrol study. Nephrol Dial Transplant 2002; 17: 1936-1941 (Pubitemid 35277091)
78. Ix JH, McCulloch CE, Chertow GM. Theophylline for the prevention of radiocontrast nephropathy: a meta-analysis. Nephrol Dial Transplant 2004; 19: 2747-2753 (Pubitemid 39480968)
79. Jordan JE, Zhao Z, Sato H, Taft S, Vinten-Johansen J. Adenosine A2 receptor activation attenuates reperfusion injury by inhibiting neutrophil accumulation, superoxide generation and coronary endothelial adherence. J Pharmacol Exp Ther 1997; 280: 301-309 (Pubitemid 27171416)
80. Lasley RD JM, Mentzer RM Jr. Beneficial effects of adenosine (2a) agonist CGS-21680 in infarcted and stunned porcine myocardium. Am J Physiol Heart Circ Physiol 2001;280;H1660-6.
81. Day YJ, Marshall MA, Huang L, McDuffie MJ, Okusa MD, Linden J. Protection from ischemic liver injury by activation of A2A adenosine receptors during reperfusion: inhibition of chemokine induction. Am J Physiol Gastrointest Liver Physiol 2004; 286: G285-93.
82. Day Y-J, Huang L, McDuffie MJ, Rosin DL, Ye H, Chen JF, et al. Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow-derived cells. J Clin Invest 2003; 112:883-891 (Pubitemid 38063746)
83. Okusa MD, Linden J, Macdonald T, Huang L. Selective A2A-adenosine receptor activation during reperfusion reduces ischemia-reperfusion injury in rat kidney. Am J Physiol 1999; 277: F404-F12.
84. Okusa MD, Linden J, Huang L, Rosin DL, Smith DF, Sullivan G. Enhanced protection from renal ischemia-reperfusion injury with A2A-adenosine receptor activation and PDE 4 inhibition. Kidney Int 2001; 59: 2114-2125 (Pubitemid 32467603)
85. Lee HT, Ota-Setlik A, Xu H, D'Agati VD, Jacobson MA, Emala CW A3 adenosine receptor knockout mice are protected against ischemia- and myoglobinuria-induced renal failure. Am J Physiol Renal Physiol 2003; 284: F267-73.
86. Lee HT, Gallos G, Nasr SH, Emala CW. A1 adenosine receptor activation inhibits inflammation, necrosis, and apoptosis after renal ischemia-reperfusion injury in mice. J Am Soc Nephrol 2004; 15:102-111 (Pubitemid 38020702)
87. Wheeler DC. Are there potential non-lipid-lowering uses of statins? Drugs 1998; 56: 517-522
88. Haslinger-Loffler B. Multiple effects of HMG-CoA reductase inhibitors (statins) besides their lipid-lowering function. Kidney Int 2008; 74: 553-555
89. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109: 1118-1126
90. Sharyo S, Yokota-Ikeda N, Mori M, Kumagai K, Uchida K, Ito K, et al. Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 2008; 74: 577-584
91. Yasuda H, Yuen PS, Hu X, Zhou H, Star RA. Simvastatin improves sepsis-induced mortality and acute kidney injury via renal vascular effects. Kidney Int 2006; 69: 1535-1542
92. Attallah N, Yassine L, Musial J, Yee J, Fisher K. The potential role of statins in contrast nephropathy. Clin Nephrol 2004; 62: 273-278 (Pubitemid 39386803)
93. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: an analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849 (Pubitemid 41097461)
94. Jo SH, Koo BK, Park JS, Kang HJ, Cho YS, Kim YJ, et al. Prevention of radiocontrast medium-induced nephropathy using short-term high-dose simvastatin in patients with renal insufficiency undergoing coronary angiography (PROMISS) trial--a randomized controlled study. Am Heart J 2008; 155: 499 e1-8.
95. Smirnov AN. Nuclear receptors: nomenclature, ligands, mechanisms of their effects on gene expression. Biochemistry (Mosc). 2002; 67: 957-977
96. Kliewer SA, Forman BM, Blumberg B, Ong ES, Borgmeyer U, Mangelsdorf DJ, et al. Evans RM Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. Proc Natl Acad Sci USA 1994; 91: 7355-7359 (Pubitemid 24226862)
97. Li S, Basnakian A, Bhatt R, Megyesi J, Gokden N, Shah SV, et al. PPAR-alpha ligand ameliorates acute renal failure by reducing cisplatin-induced increased expression of renal endonuclease G. Am J Physiol Renal Physiol 2004; 287: F990-8.
98. Li S, Wu P, Yarlagadda P, Vadjunec NM, Proia AD, Harris RA, et al. PPAR alpha ligand protects during cisplatin-induced acute renal failure by preventing inhibition of renal FAO and PDC activity. Am J Physiol Renal Physiol 2004; 286: F572-80.
99. Portilla D. Energy metabolism and cytotoxicity. Semin Nephrol 2003; 23: 432-438
100. Portilla D, Dai G, Peters JM, Gonzalez FJ, Crew MD, Proia AD. Etomoxir-induced PPARalpha-modulated enzymes protect during acute renal failure. Am J Physiol Renal Physiol 2000; 278: F667-75.
101. Feldkamp T, Kribben A, Roeser NF, Senter RA, Weinberg JM. Accumulation of nonesterified fatty acids causes the sustained energetic deficit in kidney proximal tubules after hypoxiareoxygenation. Am J Physiol Renal Physiol 2006; 290: F465-77.
102. Nagothu KK, Bhatt R, Kaushal GP, Portilla D. Fibrate prevents cisplatin-induced proximal tubule cell death. Kidney Int 2005; 68:2680-2693 (Pubitemid 43251013)
103. Kaikaus RM, Chan WK, Ortiz de Montellano PR, Bass NM. Mechanisms of regulation of liver fatty acid-binding protein. Mol Cell Biochem 1993; 123: 93-100. (Pubitemid 23249820)
104. Reddy JK. Peroxisome proliferators and peroxisome proliferator-activated receptor alpha: biotic and xenobiotic sensing. Am J Pathol 2004; 164: 2305-2321 (Pubitemid 38669376)
105. Negishi K, Noiri E, Maeda R, Portilla D, Sugaya T, Fujita T. Renal L-type fatty acid-binding protein mediates the bezafibrate reduction of cisplatin-induced acute kidney injury. Kidney Int 2008; 73: 1374-1384 (Pubitemid 351770480)
106. Daynes RA, Jones DC. Emerging roles of PPARs in inflammation and immunity. Nat Rev Immunol 2002; 2: 748-759
107. Li S, Gokden N, Okusa MD, Bhatt R, Portilla D. Anti-inflammatory effect of fibrate protects from cisplatin-induced ARF. Am J Physiol Renal Physiol 2005; 289: F469-80.
108. Noiri E, Peresleni T, Miller F, Goligorsky MS. In vivo targeting of inducible NO synthase wtih oligodeoxynucleotides protects rat kidneys against ischemia. J Clin Invest 1996; 97: 2377-2383
109. Doi K, Suzuki Y, Nakao A, Fujita T, Noiri E. Radical scavenger edaravone developed for clinical use ameliorates ischemia/reperfusion injury in rat kidney. Kidney Int 2004; 65: 1714-1723 (Pubitemid 38591019)
110. Guz G, Demirogullari B, Ulusu NN, Dogu C, Demirtola A, Kavutcu M, et al. Stobadine protects rat kidney against ischaemia/ reperfusion injury. Clin Exp Pharmacol Physiol 2007; 34: 210-216 (Pubitemid 46148264)
111. Mosnier LO, Zlokovic BV, Griffin JH. The cytoprotective protein C pathway. Blood 2007; 109: 3161-3172
112. Sharfuddin AA, Sandoval RM, Berg DT, McDougal GE, Campos SB, Phillips CL, et al. Soluble thrombomodulin protects ischemic kidneys. J Am Soc Nephrol 2009; 20: 524-534
113. Grey S, Hau H, Salem HH, Hancock WW. Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma, or PMA: modulation of effects on CD11b and CD14 but not CD25 or CD54 induction. Transplant Proc 1993;25: 2913-2914 (Pubitemid 23314299)
114. Cheng T, Liu D, Griffin JH, Fernandez JA, Castellino F, Rosen ED, et al. Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective. Nat Med 2003; 9: 338-342 (Pubitemid 36362790)
115. Domotor E, Benzakour O, Griffin JH, Yule D, Fukudome K, Zlokovic BV. Activated protein C alters cytosolic calcium flux in human brain endothelium via binding to endothelial protein C receptor and activation of protease activated receptor-1. Blood 2003; 101: 4797-4801
116. Mosnier LO, Griffin JH. Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease-activated receptor-1 and endothelial cell protein C receptor. Biochem J 2003; 373: 65-70.
117. Riewald M, Petrovan RJ, Donner A, Mueller BM, Ruf W. Activation of endothelial cell protease activated receptor 1 by the protein C pathway. Science 2002; 296: 1880-1882 (Pubitemid 34596276)
118. Mizutani A, Okajima K, Uchiba M, Noguchi T. Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation. Blood 2000; 95: 3781-3787 (Pubitemid 30412850)
119. Gupta A, Gerlitz B, Richardson MA, Bull C, Berg DT, Syed S, et al. Grinnell BW Distinct functions of activated protein C differentially attenuate acute kidney injury. J Am Soc Nephrol 2009; 20: 267-277
120. Kerschen EJ, Fernandez JA, Cooley BC, Yang XV, Sood R, Mosnier LO, et al. Endotoxemia and sepsis mortality reduction by non-anticoagulant activated protein C. J Exp Med 2007; 204: 2439-2448 (Pubitemid 47529328)
121. Mosnier LO, Zampolli A, Kerschen EJ, Schuepbach RA, Banerjee Y, Fernandez JA, et al. Hyper-antithrombotic, non-cytoprotective Glu149Ala-activated protein C mutant. Blood 2009; 113: 5970-5978
122. Westenfelder C, Biddle DL, Baranowski RL. Human, rat, and mouse kidney cells express functional erythropoietin receptors. Kidney Int 1999; 55: 808-820 (Pubitemid 29100693)
123. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, et al. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. J Am Soc Nephrol 2004; 15: 2115-2124 (Pubitemid 39031350)
124. Vaziri ND, Zhou XJ, Liao SY. Erythropoietin enhances recovery from cisplatin-induced acute renal failure. Am J Physiol 1994; 266:F360-6.
125. Yokomaku Y, Sugimoto T, Kume S, Araki S, Isshiki K, Chin-Kanasaki M, et al. Asialoerythropoietin prevents contrast-induced nephropathy. J Am Soc Nephrol 2008; 19: 321-328
126. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, et al. Prevention of Acute Kidney Injury by Erythropoietin in Patients Undergoing Coronary Artery Bypass Grafting: A Pilot Study. Am J Nephrol 2009; 30: 253-260